Skip to content

Evaluation of the Effects of Fungal-Derived Ingredients on Immune Function and Physical Condition

Evaluation of the Effects of Fungal-Derived Ingredients on Immune Function and Physical Condition - Evaluation of the Effects of Fungal-Derived Ingredients on Immune Function and Physical Condition

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059086
Enrollment
30
Registered
2025-09-15
Start date
2025-09-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese adult

Interventions

Consumption of test food once a day for 4 weeks Consumption of placebo once a day for 4 weeks

Sponsors

Medical Corporation Hokubukai Utsukushigaoka Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy males and females aged 18 to 69 years old when consent acquisition. 2) Subjects who feel catch colds easily and have caught a cold in the past 3 years. 3) Subjects who have not been vaccinated since June 2025, and who do not plan to receive new vaccinations after consent is obtained until the end of the study. 4) Individuals who have not been infected with an infectious disease (influenza or novel coronavirus) in the past year 5) Subjects who have understood the purpose and contents of the study and agree to participate by signing the written informed consent.

Exclusion criteria

Exclusion criteria: 1) Subjects using medical products. 2) Subjects who under treatment or with history of erious diabetes, kidney damage, hepatopathy and heart disease, hyroid disease, adrenal disease and other metabolic diseases. 3) Subjects who have a history of gastrointestinal disease (excluding a history of cecum). 4) Subjects who routinely take supplements that enhance immune function (agaricus, cordyceps, ericaceus, reishi mushroom, sparassis crispa, fucoidan, propolis, and lactic acid bacteria that promote the effectiveness of immune dunction). 5) Subjects who have chronic diseases and regularly use medicines. 6) Subjects who may have allergic symptoms to test foods, and subjects who may have allergic symptoms to other foods and medicines. 7) Subjects who routinely take steroids that may affect test results. 8) Subjects donated 200mL of blood in the past month or more than 400mL within 3 months. 9) Subjects with serious anemia. 10) Subjects who have tested positive for infectious disease (Syphilis, hepatitis B). 11) Subjects who have a history of drug dependence or alcohol dependence, or those who have a history of current illness. 12) Subjects who with eating disorders. 13) Subjects who take an amount of alcohol over 60g/day. 14) Subjects with possible changes of life style during the clinical studies. 15) Subjects who intend to become pregnant or lactating. 16) Subjects who participated in other clinical studied in the past 3 month. 17) Subjects judged as unsuitable for the study by the investigator for other reasons.

Design outcomes

Primary

MeasureTime frame
Mucosal immune function

Secondary

MeasureTime frame
Cytokine production, IgA, physical condition questionnaire, diary, and safety.

Countries

Japan

Contacts

Public ContactAyana Shio

Medical Corporation Hokubukai Utsukushigaoka Hospital Clinical Pharmacology Center

info@ughp-cpc.jp011-882-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026